53BP1

:   p53‐binding protein 1

AID

:   activation‐induced cytidine deaminase

ATM

:   Ataxia telangiectasia mutated

CSR

:   class switch recombination

DDR

:   DNA damage response signaling

DNA‐PKcs

:   DNA‐dependent protein kinase, catalytic subunit

DNA‐PK

:   DNA‐dependent protein kinase (holoenzyme)

DSB

:   DNA double‐strand break

HRP

:   Horseradish peroxidase

Ig

:   immunoglobulin

IL

:   interleukin

Lig4

:   DNA ligase 4

LPS

:   lipopolysaccharide

NHEJ

:   nonhomologous end joining

PAXX

:   paralogue of XRCC4 and XLF

RAG1/2

:   recombination activating genes 1 and 2

SCID

:   severe combined immunodeficiency

T‐FISH

:   telomere fluorescence *in situ* hybridization

UNG

:   uracil DNA N‐glycosylase

XLF

:   XRCC4‐like factor

XLS

:   XRCC4‐like small protein

XRCC4

:   X‐ray cross‐complementing protein 4

Nonhomologous end joining (NHEJ) recognizes and repairs DNA double‐strand breaks (DSBs) throughout the cell cycle [1](#feb412381-bib-0001){ref-type="ref"}. NHEJ is required to maintain genomic stability in response to extrinsically and physiologically induced DSBs. The latter includes DNA breaks generated by the recombination activating genes (RAG1/2) during V(D)J recombination in developing B and T lymphocytes. Activation‐induced cytidine deaminase (AID) converts cytosine to uracil at the actively transcribed switch regions of immunoglobulin heavy‐chain coding regions in mature B lymphocytes, and in cooperation with uracil DNA N‐glycosylase (UNG), it produces single‐strand breaks in both DNA strands leading to DSBs that are recognized and repaired by NHEJ [1](#feb412381-bib-0001){ref-type="ref"}, [2](#feb412381-bib-0002){ref-type="ref"}. NHEJ includes core subunits, Ku70 and Ku80 (or X‐ray repair cross‐complementing proteins, XRCC6 and XRCC5, respectively) that form the Ku heterodimer, which recognizes DSBs and serves as a platform to recruit and stabilize other NHEJ subunits. X‐ray cross‐complementing protein 4 (XRCC4) and DNA ligase 4 (Lig4) form another heterodimer that ligates DNA ends. There are several known accessory NHEJ factors that likely work downstream of Ku, upstream or in cooperation with XRCC4/Lig4, and are required in specific cases. Among them DNA‐dependent protein kinase, catalytic subunit (DNA‐PKcs), which is a protein kinase that forms the DNA‐PK holoenzyme with Ku70/Ku80 and phosphorylates most NHEJ factors, including itself. DNA‐PKcs is specifically required for stabilization and activation of the nuclease Artemis that processes RAG‐induced DNA hairpins and overhangs during V(D)J recombination. The inactivation of any core NHEJ factor, as well as DNA‐PKcs and Artemis, results in severe immunodeficiency associated with B and T lymphocytopenia, due to the inability of B and T progenitors to perform V(D)J recombination and thus to mature (reviewed in Ref. [1](#feb412381-bib-0001){ref-type="ref"}).

XRCC4‐like factor (XLF, also known as Nhej1 or Cernunnos) is considered both a core and an accessory factor in NHEJ. Similar to core NHEJ factors, XLF is evolutionary conserved in eukaryotic cells from yeast to humans. It also suppresses medulloblastoma development in p53‐deficient background [3](#feb412381-bib-0003){ref-type="ref"}. On the other hand, *Xlf* inactivation alone does not lead to a severe phenotype in mice, likely due to its functional overlap with other accessory NHEJ factors [4](#feb412381-bib-0004){ref-type="ref"}, [5](#feb412381-bib-0005){ref-type="ref"} and potentially with the Ataxia telangiectasia mutated (ATM)‐dependent DNA damage response (DDR) pathway [1](#feb412381-bib-0001){ref-type="ref"}, [6](#feb412381-bib-0006){ref-type="ref"}, [7](#feb412381-bib-0007){ref-type="ref"}, [8](#feb412381-bib-0008){ref-type="ref"}. XLF was also shown to have functional overlap with RAG recombinase, which is likely lymphocyte‐specific [9](#feb412381-bib-0009){ref-type="ref"}. *Xlf* inactivation in combination with, for example, knockout of *Atm*, histone *H2ax*, DNA damage response factor *p53‐binding protein 1* (*53BP1*), or RAG2 truncation leads to a block in lymphocyte development and thus a severe reduction in B and T lymphocyte numbers [1](#feb412381-bib-0001){ref-type="ref"}, [5](#feb412381-bib-0005){ref-type="ref"}, [9](#feb412381-bib-0009){ref-type="ref"}. It is very likely that other accessory NHEJ or DDR factors complement the roles of XLF in DNA repair and lymphocyte development.

PAXX (also known as C9Orf142, or XRCC4‐like small protein) is an accessory NHEJ factor reported by several research groups in 2015 [10](#feb412381-bib-0010){ref-type="ref"}, [11](#feb412381-bib-0011){ref-type="ref"}, [12](#feb412381-bib-0012){ref-type="ref"}. *PAXX*‐deficient human, murine, and chicken cells displayed an increased sensitivity to DSBs induced by ionizing radiation [10](#feb412381-bib-0010){ref-type="ref"}, [11](#feb412381-bib-0011){ref-type="ref"}, [12](#feb412381-bib-0012){ref-type="ref"}. In experiments based on knockout chicken and murine cells, PAXX was shown to have some functional redundancy with its paralogue XLF [12](#feb412381-bib-0012){ref-type="ref"}, [13](#feb412381-bib-0013){ref-type="ref"}, [14](#feb412381-bib-0014){ref-type="ref"}, [15](#feb412381-bib-0015){ref-type="ref"}, [16](#feb412381-bib-0016){ref-type="ref"}. In addition, three knockout mouse models were generated at different laboratories and published recently [17](#feb412381-bib-0017){ref-type="ref"}, [18](#feb412381-bib-0018){ref-type="ref"}, [19](#feb412381-bib-0019){ref-type="ref"}. These studies suggest that PAXX has an overlapping function with XLF and is required for embryonic development and maintenance of central nervous system. However, the role of PAXX on the organismal level requires further investigation.

To determine the physiological role of PAXX, we generated a *Paxx*‐deficient knockout mouse model. We compared *Paxx* null mice with wild‐type (WT) and NHEJ‐deficient controls, including the *Ku80*‐, *Dna‐pkcs*‐deficient, and severe combined immunodeficiency (SCID) mice. We found that *Paxx* null mice do not differ from WT and heterozygous littermates in viability, lymphoid organ development, class switch recombination (CSR) efficiency, and genomic stability.

Materials and methods {#feb412381-sec-0002}
=====================

Mouse models {#feb412381-sec-0003}
------------

All experiments involving mice were performed according to the protocols approved by the Norwegian University of Science and Technology (NTNU). *Ku80* ^*+/−*^ [20](#feb412381-bib-0020){ref-type="ref"}, *Dna‐pkcs* ^*+/−*^ [21](#feb412381-bib-0021){ref-type="ref"}, SCID [22](#feb412381-bib-0022){ref-type="ref"}, and *Ung* ^*+/−*^ [23](#feb412381-bib-0023){ref-type="ref"} mice were described previously. *Paxx* ^*+/−*^ mice are custom‐generated and described here for the first time.

Generation of *Paxx* ^*−/−*^ mice {#feb412381-sec-0004}
---------------------------------

*Paxx*‐deficient (*Paxx* ^*−/−*^) mice were generated upon request as OKS1 project by genOway (Lyon, France). Analysis of the *Paxx* gene structure showed that another gene *Clic3* overlaps with the *Paxx*. Thus, only the part of *Paxx* gene that does not overlap with *Clic3* was deleted. Two sgRNAs were designed to target the promoter region and the end of exon 2 of the *Paxx* gene: sgRNA\#1, CCC AAG GGC TTG TAC TGC; sgRNA\#2, GGC GGC GTC CGT CAC ACT. Fertilized oocytes were collected from superovulated female mice previously mated with males. The purified sgRNAs and Cas9 RNA were microinjected into the male pronucleus. Injected zygotes were cultivated overnight to the two‐cell stage to assess sgRNAs toxicity. Resulting two‐cell embryos were reimplanted into pseudopregnant foster mothers 0.5 day *post coitum*. A total of 158 injected embryos were reimplanted into foster mothers, leading to the birth of 60 viable pups.

Mouse screening strategy {#feb412381-sec-0005}
------------------------

The screening was performed on genomic DNA extracted from mouse skin. Two primers were used to amplify the original or modified part of the *Paxx* gene. The intact gene results in a 965‐bp product and deletion resulted in shorter products ranging from 280 to 412 bp, depending on the size of deletion. Four founder mice were identified in which mutation was confirmed by sequencing at genOway. Three heterozygous *Paxx*‐knockout lines were obtained by backcrossing founders to C57BL6/N WT mice. The primers to detect deletion in murine *Paxx* gene were as follows: ACA GAG GGT GGT GAC TCA GAC AAT GG and GGA AAT GCT ATT AGA ACC ACT GCC ACG.

Antibodies {#feb412381-sec-0006}
----------

To detect the PAXX protein by western blot, we used rabbit polyclonal anti‐PAXX/C9orf142 IgG (NovusBio, Littleton, CO, USA, NBP1‐94172, dilution 1 : 500), which recognizes the C‐terminal half of the PAXX protein (amino acids 109‐204); anti‐PAXX/C9orf142 IgG (Abcam, Cambridge, UK, ab126353, 1 : 200) and swine polyclonal anti‐rabbit Ig‐HRP (Dako antibodies, \#P0399, 1 : 3000). Anti‐GAPDH rabbit polyclonal (Sigma, St. Louis, MO, USA, \#G9545, developed to recognize 314--333 amino acids of mouse GAPDH, 1 : 2000) and mouse monoclonal anti‐β‐actin (Abcam, ab8226, 1 : 3000) with rabbit polyclonal anti‐mouse Ig‐HRP (Dako antibodies, \#P0260, 1 : 3000) were used to control protein loading.

CSR to IgG1, tail fibroblasts, telomere FISH (T‐FISH), statistical analyses {#feb412381-sec-0007}
---------------------------------------------------------------------------

CSR to IgG1 was performed as previously described in Refs [4](#feb412381-bib-0004){ref-type="ref"}, [8](#feb412381-bib-0008){ref-type="ref"}, [24](#feb412381-bib-0024){ref-type="ref"}. Briefly, splenic B cells were isolated by negative selection using magnetic immunolabelling with an EasySep™ Mouse B Cell Isolation Kit (Stemcell, Cambridge, UK, \#19854), stimulated with IL‐4 and lipopolysaccharide (LPS), and analyzed by flow cytometry at day 4. Antibody used for IgG1 detection was anti‐IgG1‐APC (BD Biosciences, Franklin Lakes, NJ, USA, \#550874). Primary murine tail fibroblasts were generated and cultured as previously described [4](#feb412381-bib-0004){ref-type="ref"}, [5](#feb412381-bib-0005){ref-type="ref"}, [7](#feb412381-bib-0007){ref-type="ref"}. T‐FISH was performed as previously described [4](#feb412381-bib-0004){ref-type="ref"}, [5](#feb412381-bib-0005){ref-type="ref"}, [7](#feb412381-bib-0007){ref-type="ref"}. Statistical analyses were performed using [graphpad prism]{.smallcaps} 7.03 (La Jolla, CA, USA), one‐way ANOVA.

Histological brain analysis {#feb412381-sec-0008}
---------------------------

We isolated brains of 5‐week‐old mice, fixed them with 4% formaldehyde for 15 days, paraffin‐embedded, and sectioned (4 μm). Nissl staining was performed as described in Ref. [25](#feb412381-bib-0025){ref-type="ref"}. Briefly, after deparaffinization and hydration, the sections were immersed in 0.1% cresyl violet acetate (Sigma) for 5 min. Then, the samples were rinsed with distilled water and dehydrated in ethanol, cleared in Clear‐Rite™ 3 (Thermo Fisher Scientific, Waltham, MA, USA), and mounted with Entall^®^New (Merck Millipore, Burlington, MA, USA). Images were taken with Nikon D5‐Fi2 microscope (Nikon, Tokyo, Japan). Figures were analyzed to distinguish between apoptotic cells harboring pyknotic nuclei (strong staining, rounded shape, and smaller size) from proliferative cells (strong staining, flattened cells with a lot of cytoplasm around nuclei). Terminal deoxynucleotide transferase‐mediated dUTP nick end labeling (TUNEL) assay was performed by In Situ Cell Death Detection Kit, TMR red Protocol (Roche, Basel, Switzerland) following the manufacturer\'s guide. Briefly, the sections were deparaffinized by heating and hydrated with decreasing concentrations of ethanol. Then, the samples were treated with proteinase K for 20 min at 37 °C and washed with 1× PBS (Sigma). Sections were incubated in a terminal deoxynucleotidyl transferase (TdT) reaction mix for 1 h at 37 °C, washed with PBS, and mounted with Vectashield (Vector Laboratories, Burlingame, CA, USA). Images were taken with Zeiss LSM 510 Meta microscope (Nikon).

Results {#feb412381-sec-0009}
=======

Generation of *Paxx* ^*−/−*^ mice {#feb412381-sec-0010}
---------------------------------

To identify the physiological role of PAXX, we generated a mouse model with deletion of part of the *Paxx* locus on a C57BL6/N background (Fig. [1](#feb412381-fig-0001){ref-type="fig"}). For this, the purified sgRNAs and Cas9 RNA were microinjected into the fertilized oocytes, resulting in a locus deletion and complete inactivation of the *Paxx* gene function. A total of 158 injected embryos were reimplanted into foster mothers leading to 60 viable pups. Four *Paxx* F0 null founders that carried 538‐ to 670‐bp deletions covering the *Paxx* promoter and exons 1--2 were identified by PCR screening (Fig. [1](#feb412381-fig-0001){ref-type="fig"}B) and DNA sequencing. The founders were backcrossed to C57BL6/N WT mice, and the first heterozygous generation was used to establish colonies. The resulting *Paxx*‐deficient mice (*Paxx* ^*−/−*^) showed complete absence of the PAXX protein in tail fibroblasts, spleen, thymus, liver, and lungs when compared to *Paxx* ^*+/+*^ and *Paxx* ^*+/−*^ littermates (Fig. [1](#feb412381-fig-0001){ref-type="fig"}C--E). These results we verified using two independent antibodies, one from NovusBio and one from Abcam, both generated to recognize the C‐terminal half, 109--204 amino acids of human PAXX protein. Moreover, haploinsufficiency for *Paxx* resulted in reduced PAXX protein level in *Paxx* ^*+/−*^ cells compared to *Paxx* ^*+/+*^ controls, as shown for tail fibroblasts and liver (Fig. [1](#feb412381-fig-0001){ref-type="fig"}C--E). We concluded that our *Paxx* ^*−/−*^ mice do not express PAXX.

![Generation of *Paxx* ^*−/−*^ mice. (A) Top. Schematic diagram of murine *Paxx* locus indicating the ATG and STOP sites, and the targeted loci in the promoter region for sgRNA\#1 and in exon 2 for sgRNA\#2. Bottom. Resulting *Paxx* ^*−/−*^ locus lacking part of the promoter region, transcription start site, and exon 1. (B) PCR‐based genotyping strategy reveals the *Paxx* wt allele (965 bp) and *Paxx* null allele (270 bp). The following samples are presented, from left to right: two *Paxx* ^*+/+*^ and two *Paxx* ^*−/−*^. (C,D) Western blot analyses using *Novus* anti‐PAXX immunoglobulins revealed the lack of PAXX protein in *Paxx* ^*−/−*^ tail fibroblasts, spleen, thymus, liver, and lungs when compared to *Paxx* ^*+/+*^ controls and reduction of PAXX protein in *Paxx* ^*+/−*^ cells. (E) Western blot using *Abcam* anti‐PAXX immunoglobulins showed no PAXX protein in *Paxx* ^*−/−*^ and reduction of PAXX protein in *Paxx* ^*+/−*^ livers compared to *Paxx* ^*+/+*^. (F) Analyses of 184 pups born from *Paxx* ^*+/−*^ parents revealed expected genetic distribution of *Paxx* ^*+/+*^ (43), *Paxx* ^*+/−*^ (89), and *Paxx* ^*−/−*^ (52) mice, which is close to 1 : 2 : 1 distribution. (G) Body weight of 30‐day‐old *Paxx* ^*+/+*^ mice (*n *=* *43) is not distinguishable from *Paxx* ^*+/−*^ (*n *=* *60, *P *=* *0.9559) and *Paxx* ^*−/−*^ mice (*n *=* *99, *P *=* *0.9629). Six *Ku80* ^*−/−*^ mice of the same age were significantly smaller than *Paxx* ^*+/+*^, *Paxx* ^*+/−*^, and *Paxx* ^*−/−*^ mice, *P *\<* *0.0001. (H) Example of 5‐week‐old mice, *Paxx* ^*+/+*^, two *Paxx* ^*+/−*^, and *Paxx* ^*−/−*^, as indicated.](FEB4-8-426-g001){#feb412381-fig-0001}

*Paxx* ^*−/−*^ mice are viable and grow normally {#feb412381-sec-0011}
------------------------------------------------

The inactivation of one or both *Paxx* alleles resulted in viable and fertile mice indistinguishable by size from WT littermates (Fig. [1](#feb412381-fig-0001){ref-type="fig"}F--H). The pups from *Paxx* ^*+/−*^ parents were born at the expected 1 : 2 : 1 proportion, 43 *Paxx* ^*+/+*^, 89 *Paxx* ^*+/−*^, and 52 *Paxx* ^*−/*−^ mice (Fig. [1](#feb412381-fig-0001){ref-type="fig"}F). At day 30, the average size of *Paxx* ^*+/+*^, *Paxx* ^*+/−*^, and *Paxx* ^*−/−*^ mice was not significantly different; all these mice were larger than *Ku80* ^*−/−*^ mice which are known to have reduced body size (Fig. [1](#feb412381-fig-0001){ref-type="fig"}G,H). To further describe our *Paxx* ^*−/−*^ mouse model, we performed Nissl staining and TUNEL assay on brain sagittal sections of 5‐week‐old mice. Nissl staining revealed that the morphology of the *Paxx* ^*−/−*^ brain was identical to WT littermates. According to this, the presence of apoptotic cell WT brains did not outnumber the apoptotic cells found in *Paxx* ^*−/−*^. Proliferative cells were found in both genotypes at similar proportion (not shown). TUNEL assay revealed that the levels of apoptosis were almost undetectable in both *Paxx* ^*−/−*^ and WT brains. We concluded that inactivation of *Paxx* alone did not affect growth, size, fertility, and development of central nervous system in mice, which is in line with recently published three independent *Paxx*‐knockout mouse models [17](#feb412381-bib-0017){ref-type="ref"}, [18](#feb412381-bib-0018){ref-type="ref"}, [19](#feb412381-bib-0019){ref-type="ref"}.

*Paxx* ^*−/−*^ mice develop normal lymphoid organs {#feb412381-sec-0012}
--------------------------------------------------

Neither spleen nor thymus development was affected in the absence of PAXX (Fig. [2](#feb412381-fig-0002){ref-type="fig"}). The average spleen sizes at 45 days were 70, 67, and 73 mg for *Paxx* ^*+/+*^, *Paxx* ^*+/−*^, and *Paxx* ^*−/−*^, respectively (no significant difference), while it was reduced in NHEJ‐deficient *Ku80* ^*−/−*^ (15 mg) and *Dna‐pkcs* ^*−/−*^ (21 mg) mice of the same age, *P *\<* *0.0001 (Fig. [2](#feb412381-fig-0002){ref-type="fig"}A,C). The average splenocyte counts were similar in *Paxx* ^*+/+*^, *Paxx* ^*+/−*^, and *Paxx* ^*−/−*^ mice (108, 126, and 108 million, respectively, *P *\>* *0.1415, Fig. [2](#feb412381-fig-0002){ref-type="fig"}B). Thymus weight was also comparable between *Paxx* ^*+/+*^, *Paxx* ^*+/−*^, and *Paxx* ^*−/−*^ mice (84, 101, and 83 mg, respectively) (Fig. [2](#feb412381-fig-0002){ref-type="fig"}D,F). The thymocyte count was also similar between *Paxx* ^*+/+*^, *Paxx* ^*+/−*^, and *Paxx* ^*−/−*^ mice (199, 226, 179 million, respectively) (Fig. [2](#feb412381-fig-0002){ref-type="fig"}E). Total count of cells in bone marrow was similar in *Paxx* ^*+/+*^, *Paxx* ^*+/−*^, and *Paxx* ^*−/−*^ mice (*P *\> 0.1546, Fig. [2](#feb412381-fig-0002){ref-type="fig"}G). Thus, we concluded that PAXX is dispensable for development of lymphoid tissue in mice.

![Development of lymphoid organs in *Paxx* ^*−/−*^ mice. (A) The weight of spleens isolated from *Paxx* ^*+/+*^ (*n *=* *26), *Paxx* ^*+/−*^ (*n *=* *13), and *Paxx* ^*−/−*^ (*n *=* *17). Six‐week‐old mice were not significantly different, with *P *\>* *0.4677. Spleen size in immunodeficient *Ku80* ^*−/−*^ and *Dna‐pkcs* ^*−/−*^ mice was significantly reduced, correspondingly; both pairs, *Paxx* ^*−/−*^ vs *Ku80* ^*−/−*^, and *Paxx* ^*−/−*^ vs *Dna‐pkcs* ^*−/−*^, have *P *\<* *0.0001. (B) Splenocyte count is not affected in *Paxx* ^*−/−*^ mice when compared to WT littermates, *P *\>* *0.1566. (C) Example of spleens isolated from *Dna‐pkcs* ^*−/−*^, *Paxx* ^*−/−*^, *Paxx* ^*+/−*^, and *Paxx* ^*+/+*^ mice. (D) The weight of thymus from *Paxx* ^*+/+*^ (*n *=* *16), *Paxx* ^*+/−*^ (*n *=* *6), and *Paxx* ^*−/−*^ (*n *=* *9) is similar with *P *\>* *0.9255. (E) Thymocyte count was nearly identical in *Paxx* ^*+/+*^ (*n *=* *9), *Paxx* ^*+/−*^ (*n *=* *7), and *Paxx* ^*−/−*^ (*n *=* *9) mice, *P *\>* *0.2649. (F) Example of thymi from *Paxx* ^*−/−*^, *Paxx* ^*+/−*^, and *Paxx* ^*+/+*^ mice. (G) Count of total cells in bone marrow was similar in *Paxx* ^*+/+*^ (*n *=* *9), *Paxx* ^*+/−*^ (*n *=* *3), and *Paxx* ^*−/−*^ (*n *=* *6) mice, *P *\>* *0.1546. (H) CSR to IgG1 was identical in *Paxx* ^*+/+*^ (*n *=* *7), *Paxx* ^*+/−*^ (*n *=* *2), and *Paxx* ^*−/−*^ (*n *=* *3) mice. CSR to IgG1 was significantly reduced in *Ung* ^*−/−*^ B cells when compared to *Paxx* ^*−/−*^ (*n *=* *6), *P *\<* *0.0001.](FEB4-8-426-g002){#feb412381-fig-0002}

*Ex vivo* stimulated primary *Paxx* ^*−/−*^ B lymphocytes exhibit normal CSR levels {#feb412381-sec-0013}
-----------------------------------------------------------------------------------

Deleting of XLF and XRCC4 results in a twofold to threefold reduction in CSR activity, which can be explained by the activity of alternative end joining (A‐EJ) in the *Xrcc4* ^*−/−*^ cells [24](#feb412381-bib-0024){ref-type="ref"} and the residual activity of both classical NHEJ and A‐EJ in *Xlf* ^*−/−*^ cells [3](#feb412381-bib-0003){ref-type="ref"}, [8](#feb412381-bib-0008){ref-type="ref"}. To determine the role of PAXX in CSR, we isolated primary splenic B lymphocytes from *Paxx* ^*+/+*^, *Paxx* ^*+/−*^, and *Paxx* ^*−/−*^ mice and stimulated them with bacterial LPS and interleukin 4 to undergo CSR. Four days after stimulation, CSR levels to IgG1 in *Paxx* ^*+/+*^ and *Paxx* ^*−/−*^ cells ranged from 23.4% to 31.3% and were not significantly different (Fig. [2](#feb412381-fig-0002){ref-type="fig"}H), *P *=* *0.5226. B cells from *Ung* ^*−/−*^ mice were used as negative control and switched at background levels, 0.4--1.2% of IgG1^+^ B cells, in line with original observations [26](#feb412381-bib-0026){ref-type="ref"} (Fig. [2](#feb412381-fig-0002){ref-type="fig"}H). We therefore concluded that PAXX is dispensable for CSR in mice.

*Paxx* ^*−/−*^ mice exhibit no change in genomic stability {#feb412381-sec-0014}
----------------------------------------------------------

We have previously demonstrated that inactivation of the core NHEJ factor *Ku70* results in a threefold to sixfold increase of aberrant metaphases in murine tail fibroblasts measured as chromosomal and chromatid breaks compared to WT controls. In addition, inactivation of *Xlf* and *Dna‐pkcs* resulted in a significant though moderate increase in the proportion of aberrant metaphases [1](#feb412381-bib-0001){ref-type="ref"}, [4](#feb412381-bib-0004){ref-type="ref"}, [5](#feb412381-bib-0005){ref-type="ref"}, [7](#feb412381-bib-0007){ref-type="ref"}. To determine whether *Paxx* inactivation affects genomic stability, we measured metaphase aberrations in isolated tail fibroblasts from five *Paxx* ^*+/+*^ and five *Paxx* ^*−/−*^ mice, using three *Ku80* ^*−/−*^ mice as NHEJ‐deficient controls. We found that the average proportion of aberrant metaphases was identical in *Paxx* ^*+/+*^ and *Paxx* ^*−/−*^ mice (8%, *P *\>* *0.9999), while significantly increased to 33% in *Ku80* ^*−/−*^ mice (*P *\<* *0.0001) (Fig. [3](#feb412381-fig-0003){ref-type="fig"}). We concluded that PAXX is dispensable for genomic stability in mice.

![Analyses of genomic instability in *Paxx* ^*−/−*^ tail fibroblasts. (A) Summary of genomic instability in *Paxx* ^*+/+*^ (WT,*n *=* *5), *Paxx* ^*−/−*^ (*n *=* *5), and *Ku80* ^*−/−*^ (*n *=* *3) mouse tail fibroblasts. (B) Proportion of aberrant metaphases in tail fibroblasts of indicated genotypes. (C) Example of metaphase spread from one *Ku80* ^*−/−*^ mouse tail fibroblast (right). Intact chromosomes with four telomeric signals, chromosomal and chromatid breaks with 2, 3, and 1 telomeric signals, correspondingly, are indicated at the selected area (left).](FEB4-8-426-g003){#feb412381-fig-0003}

Discussion {#feb412381-sec-0015}
==========

Here, we report the newly generated *Paxx* ^*−/−*^ knockout mouse model. We deleted part of the *Paxx* promoter region, transcription start site, and exons1--2. We did not delete the entire *Paxx* locus because it overlaps with other genes. In particular, prostaglandin‐H2 D‐isomerase (*Ptgds*) is in sense orientation 5.6 kb upstream of *Paxx*, chloride intracellular channel protein 3 (*Clic3*) overlaps with *Paxx* intron 3, and ATP‐binding cassette subfamily A member 2 (*Abca2*) is in antisense orientation 6.6 kb downstream of *Paxx*.

Inactivation of both alleles of *Paxx* in mice resulted in no detectable protein levels in tail fibroblasts, spleen, thymus, liver, and lungs. Furthermore, it did not affect growth, fertility, development of lymphoid organs, or genomic stability of mice, when compared to heterozygous or WT littermates. In addition, PAXX was dispensable for CSR to IgG1 in primary B splenocytes, which is in line with data obtained using knockout B‐cell CH12F3 cell lines, where inactivation of *Paxx* did not affect CSR to IgA \[[14](#feb412381-bib-0014){ref-type="ref"},[27](#feb412381-bib-0027){ref-type="ref"}\]. Finally, we analyzed brain sections of WT and *Paxx* ^*−/−*^ mice and found no difference in neurodevelopment using two independent methods, Nissl staining and TUNEL assay (not shown).

While our mouse model was produced and analyzed, three other groups independently reported *Paxx*‐deficient mice [17](#feb412381-bib-0017){ref-type="ref"}, [18](#feb412381-bib-0018){ref-type="ref"}, [19](#feb412381-bib-0019){ref-type="ref"}. In contrast to our mouse model, those mice had the entire *Paxx* locus deleted. These groups found that PAXX is dispensable for mouse development unless its paralogue XLF is also inactivated. Moreover, *Paxx* ^*−/−*^ *Xlf* ^*−/−*^ mice are embryonically lethal, which limits further studies of the functional interaction between PAXX and XLF in adult animals. One option to bypass this challenge is to generate conditional knockout genes for *Xlf, Paxx*, or both genes. This would enable the specific deletion of *Xlf a*nd *Paxx* in organs of interest, such as the spleen, thymus, or brain. However, conditional knockouts are often limited by, for example, incomplete deletion. Previously, it has been demonstrated that the inactivation of *Ku80* rescues embryonic lethality in *Lig4* ^*−/−*^ mice [28](#feb412381-bib-0028){ref-type="ref"}, and *Ku70* inactivation rescues perinatal lethality in *Xlf* ^*−/−*^ *Dna‐pkcs* ^*−/−*^ [5](#feb412381-bib-0005){ref-type="ref"}. Thus, the inactivation of upstream NHEJ factors Ku70 or Ku80 might rescue embryonic lethality in *Paxx* ^*−/−*^ *Xlf* ^*−/−*^ mice, although it would completely inactivate residual classical NHEJ. Additionally, haploinsufficiency for the *Trp53* gene (p53) rescues embryonic lethality of *Lig4* ^*−/−*^ [29](#feb412381-bib-0029){ref-type="ref"}, *Xrcc4* ^*−/−*^ [30](#feb412381-bib-0030){ref-type="ref"}, and *Xlf* ^*−/−*^ *Dna‐pkcs* ^*−/−*^ mice [5](#feb412381-bib-0005){ref-type="ref"}. Thus, we may speculate whether a *Paxx* ^*−/−*^ *Xlf* ^*−/−*^ *Trp53* ^*+/−*^ mouse may be viable despite complete absence of PAXX and XLF in all organs and tissues allowing the study of functional interaction between *Paxx* and *Xlf in vivo*.
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